Perspective Therapeutics reports 43% response rate in [212Pb]VMT-α-NET Phase 1/2a trial

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX

0.00
  • Perspective Therapeutics presented updated interim Phase 1/2a data at AACR 2026 for its lead SSTR2-targeted radiopharmaceutical, [212Pb]VMT-α-NET, in metastatic or unresectable neuroendocrine tumors.
  • Results had been previously disclosed at ESMO 2025 and ASCO-GI 2026, with the AACR update extending follow-up and supporting continued tumor-shrinkage activity in treated patients.
  • Safety profile remained broadly consistent with earlier reads, with no new study-stopping safety signals reported in the expanded safety dataset.
  • Perspective expects initial efficacy data later in 2026 from additional patients in Cohort 2 plus first patients in Cohort 3, positioning the program for regulatory engagement during 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200600PRIMZONEFULLFEED9692723) on April 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.